Version 41.2 of the Australian guidelines for the clinical care of people with COVID-19 includes the identification of two new studies on disease-modifying treatments:
- Canakinumab NEW – one new study comparing canakinumab to placebo in 454 hospitalised patients with severe COVID-19 (Caricchio et al.)
- Azithromycin – one new study comparing azithromycin to placebo in 263 adult outpatients with COVID-19 (Oldenburg et al.)
Ends.
